Try our Advanced Search for more refined results

In re HIV Antitrust Litigation

Track this case

Case overview

Case Number:

3:19-cv-02573

See also:

Court:

California Northern

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action

Judge:

Edward M Chen

Firms

Companies

Government Agencies

Sectors & Industries:

  1. January 22, 2024

    HIV Drug Wholesalers' Attys Get $75M In Gilead Antitrust Case

    A California federal judge has given final approval to Gilead Sciences' $247 million settlement with direct purchasers of HIV medications, including an award of $75 million for attorney fees, ending claims the pharmaceutical giant worked with Teva Pharmaceuticals to delay generic versions.

  2. November 01, 2023

    Gilead And Teva Drug Buyers Lose Bid For New Antitrust Trial

    A California federal judge on Wednesday refused to grant HIV medication purchasers a new trial following a jury's verdict clearing Gilead and Teva in a $3.6 billion antitrust case claiming they had an illicit agreement to delay generic versions of the drugs, finding that the jury's decision was in line with the evidence presented and not a result of confusion as to the verdict form instructions.

  3. October 26, 2023

    Gilead Judge Leery Of Drug Buyers' New Antitrust Trial Bid

    A California federal judge on Thursday appeared critical of a bid by HIV medication purchasers to get a new trial after Gilead and Teva were cleared of claims they struck an illegal deal to delay generic versions of the drugs, suggesting concerns about the jury not following instructions have been waived.

  4. September 21, 2023

    Gilead Sciences Gets Initial OK On $247M HIV Antitrust Deal

    A California federal judge on Thursday granted preliminary approval to Gilead's deal to pay the direct purchasers of its HIV medications $246.8 million to end claims the pharmaceutical company cut a deal with Teva to delay generic versions, saying considering the litigation risks, "the settlement is a reasonable one."

  5. August 29, 2023

    CVS, Others Say Consumers Can't 'Free Ride' HIV Drugs Deal

    Different plaintiffs' counsel are fighting among themselves in antitrust litigation alleging Gilead and Teva cut a deal to delay generic versions of HIV drugs, with consumers seeking a piece of a settlement pie even after they lost at trial, and the settling retailers saying Monday the consumers have no claim.

  6. August 14, 2023

    HIV Drug Buyers Want New Antitrust Trial

    Buyers of HIV medication, including insurers United HealthCare, Humana and Kaiser, have asked a California federal court for a new trial after a jury rejected their claims that Gilead and Teva cut a deal to delay generic versions of the drugs.

  7. August 10, 2023

    Gilead Sciences Inks $247M Deal For HIV Antitrust Claims

    Gilead has agreed to pay direct purchasers of its HIV medications $246.8 million, ending claims the pharmaceutical company cut a deal with Teva to delay generic versions after reaching an initial settlement on the eve of a trial earlier this year.

  8. July 05, 2023

    How A 3-Firm 'Joint Effort' Beat A $3.6B Pharma Antitrust Suit

    With Gilead and Teva facing trial on claims they bilked health plans and insurers out of $3.6 billion through a "pay-for-delay" scheme over two HIV drugs, the three law firms representing the pharmaceutical giants secured a total victory last week by putting on a united front, attacking the reliability of the plaintiffs' experts and even waiving some attorney-client privilege.

  9. June 30, 2023

    Gilead, Teva Defeat $3.6B HIV Drug Antitrust Case At Trial

    A California federal jury cleared Gilead and Teva on Friday in a $3.6 billion antitrust case claiming the pharmaceutical giants struck an illegal "pay-for-delay" patent deal that inflated prices for two HIV medications, finding plaintiffs hadn't shown Gilead had market power or that it paid Teva to delay its generics.

  10. June 28, 2023

    Attys For Gilead, Drug Buyers Trade Barbs As $3.6B Trial Ends

    Gilead's lawyer on Wednesday slammed a $3.6 billion antitrust suit alleging an illegal "pay-for-delay" deal with Teva over two HIV drugs during closing arguments, calling the plaintiffs' theory a "house of cards," while a plaintiffs' lawyer accused the drugmakers of "sleight of hand" at trial by selectively using attorney-client privilege.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!